Therapeutic VEGFR2-antibody from the original Cyramza® commercial drug targeting the VEGFR2-antigen, also referred to as Cyramza® or ramucirumab antibody . Research-relevant quantities are available as licence-free consumable in aliquoted or diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.
What our clients say
”Evidentic can supply different batches of reference products for precilinical research.The quick access to the on-stock batches allows for adhoc ordering, keeps costs down and makes a headstart possible!”
“Evidentic is a new source of cost-efficient therapeutic mAbs for our immonassays. And easy to order!”
“We develop innovative and biosimilar mAbs for a global market. Evidentic’s aRMPs are a great source of cost-efficient reference products for our research and development program.”
“Evidentic gives rapid access to originator biologics and different batches. For biosimilar developers and regulators, it will shorten the time to gauge the analytical acceptance range for multiple CQAs of biotherapeutics.”
Ramucirumab / Cyramza
|API type||Ramucirumab is a human IgG1 monoclonal antibody produced in murine (NS0) cells by recombinant DNA technology.
|Pharmacotherapeutic group||Antineoplastic agents, monoclonal antibodies
|Target of antibody||VEGFR2; Synonyms: CD309, FLK1, VEGFR, 6130401C07, Flk-1, Flk1, Krd-1, Ly73, VEGFR-2, sVEGFR2, Vegfr-2, FLK-1, flk-1, vegfr-2, KDR, FLK/KDR, flk1, flk1b, kdrb, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, wu:fc31a09
(Mechanism of action; Source EMA document)
|Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced
angiogenesis. Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF
Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits
ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components,
including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and
migration of human endothelial cells.
|Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)|
|Original license holder|
|Marketing authorisation numbers||EU/1/14/957/001 - 003
|Marketing authorisation holder||Eli Lilly Nederland B.V.
3528 BJ Utrecht
|Name of the manufacturer of the biological active substance||ImClone Systems LLC
33 ImClone Drive,
Eli Lilly S.A.
|Name and address of the manufacturer(s) responsible for batch release||Lilly, S.A.
Avda de la Industria, 30
|Max shelf life||36 months
|Storage conditions||2°C – 8°C
|List of excipients||Histidine
Polysorbate 80 (E433)
Water for injections